Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelets are small, anucleate cell fragments circulating in blood, derived from megakaryocytes. In their resting (unactivated) state, they circulate inertly, maintained by continuous inhibition from endothelial factors such as nitric oxide and prostacyclin. Resting platelets have a distinctive discoid morphology, maintain low intracellular calcium, and possess surface molecules such as glycoprotein Ib-IX-V and GPVI in an unengaged conformation. On blood vessel injury, platelets rapidly transition to the activated state, facilitating adhesion, secretion, and aggregation to form a platelet plug and initiate coagulation. The resting state is crucial for preventing unwanted thrombosis under physiologic conditions. Unactivated platelets do not execute procoagulant functions but have the molecular machinery to respond quickly when activated.
Not applicable. Drugs target receptors or signaling molecules involved in platelet activation, e.g., P2Y12 antagonists inhibit ADP-induced platelet activation and aggregation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet (resting state) (None).